Our data showed that the prevalence of MET expression in CTCs isolated by CellSearch® is greater than previously reported data (20% MET-positive scores of 2+ or 3+), and even higher to the expected MET expression in patients with metastatic cancer. Here, MET is linked to metastatic malignant neoplasm.